BIENAIME JEAN JACQUES
Director · Ascendis Pharma A/S
Every open-market stock purchase BIENAIME JEAN JACQUES has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- ASNDAscendis Pharma A/S
2 purchases totalling $492.7K at an average of $246.33 per share. See all insider buying in ASND →
Avg price paid$246.33Latest price—Market capUnknown - IMNM+19.3% vs price paidImmunome Inc.
2 purchases totalling $220.4K at an average of $20.03 per share; the stock last traded at $23.90. See all insider buying in IMNM →
Avg price paid$20.03Latest price$23.90Market cap$2.7B - KROSKeros Therapeutics, Inc.
One purchase totalling $10.6K at an average of $10.61 per share. See all insider buying in KROS →
Avg price paid$10.61Latest price—Market capUnknown
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving BIENAIME JEAN JACQUES or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from BIENAIME JEAN JACQUES's Form 4 filings on SEC EDGAR (CIK 1221590) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.